News
TMDX
100.70
+0.29%
0.30
Most and least shorted mid-to mega-cap healthcare stocks in March
Seeking Alpha · 1d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Dexcom (DXCM)
TipRanks · 2d ago
Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Humacyte (HUMA)
TipRanks · 3d ago
Weekly Report: what happened at TMDX last week (0323-0327)?
Weekly Report · 5d ago
Weekly Report: what happened at TMDX last week (0316-0320)?
Weekly Report · 03/23 09:53
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), HOYA (OtherHOCPF) and TransMedics Group (TMDX)
TipRanks · 03/19 10:10
TransMedics: Strengthening High-Conviction Buy on Robust Growth Outlook, Next-Gen Platforms, and International Expansion Upside
TipRanks · 03/18 09:15
Weekly Report: what happened at TMDX last week (0309-0313)?
Weekly Report · 03/16 09:53
TransMedics: Rapidly Scaling Business Nears Free Cash Flow Breakeven
Seeking Alpha · 03/16 08:30
TransMedics Group Inc. Files Initial Beneficial Ownership Statement for Matthew S. Forsyth, Senior Vice President, General Counsel and Secretary
Reuters · 03/13 21:30
Reiterating Buy on TransMedics: Defensible OCS Leadership and Organ Management Expansion Drive Sustained Growth Outlook
TipRanks · 03/13 09:25
TransMedics: Early 2026 DCD and Liver Transplant Momentum Supports Upside and Maintained Buy Rating
TipRanks · 03/10 11:55
TransMedics: Trials Should Broaden OCS Adoption, Watch For Headwinds (Downgrade)
Seeking Alpha · 03/09 17:05
TransMedics: Numb Reaction To Extraordinary Fundamentals
Seeking Alpha · 03/09 14:20
TransMedics Group Price Target Raised to $130.00/Share From $115.00 by Stifel
Dow Jones · 03/09 12:58
TransMedics Group Is Maintained at Hold by Stifel
Dow Jones · 03/09 12:58
Stifel Maintains Hold on TransMedics Group, Raises Price Target to $130
Benzinga · 03/09 12:47
TransMedics price target raised to $130 from $115 at Stifel
TipRanks · 03/09 11:16
TRANSMEDICS GROUP INC <TMDX.O>: STIFEL RAISES TARGET PRICE TO $130 FROM $115
Reuters · 03/09 11:13
More
Webull provides a variety of real-time TMDX stock news. You can receive the latest news about Transmedics Group through multiple platforms. This information may help you make smarter investment decisions.
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.